Antitumor activity of Bortezomib alone and in combination with TRAIL in human acute myeloid leukemia.

被引：0
|
作者：
Conticello, Concetta [1 ]
Adamo, Luana [2 ]
Vicari, Luisa [2 ]
Giuffrida, Raffaella [2 ]
Iannolo, Gioacchin [2 ]
Anastasi, Gabriele [2 ]
Palumbo, Giuseppe A. [4 ]
Gulisano, Massimo [2 ]
De Maria, Ruggero [3 ]
Giustolisi, Rosario [4 ]
Di Raimondo, Francesco [4 ]
机构：
[1] Mediterranean Inst Oncol, Dept Expt Oncol, Viagrande, CT USA
[2] IOM Ric, Viagrande, CT USA
[3] Inst Superiore Sanita, Dept Hematol Oncol & Mol Med, Rome, Italy
[4] Univ Catania, Dept Biomed Sci, Hematol Sect, Catania, Italy
来源：
BLOOD | 2007年 / 110卷 / 11期
关键词：
D O I：
10.1182/blood.V110.11.4307.4307
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
4307
引用
收藏
页码：144B / 144B
页数：1
相关论文
共 50 条
  • [1] Antitumor activity of bortezomib alone and in combination with trail in human acute myeloid leukemia
    Conticello, Concetta
    Adamo, Luana
    Vicari, Luisa
    Giuffrida, Raffaella
    Iannolo, Gioacchin
    Anastasi, Gabriele
    Caruso, Laura
    Moschetti, Gaetano
    Cupri, Alessandra
    Palumbo, Giuseppe Antonio
    Gulisano, Massimo
    De Maria, Ruggero
    Giustolisi, Rosario
    Di Raimondo, Francesco
    ACTA HAEMATOLOGICA, 2008, 120 (01) : 19 - 30
  • [2] Antitumor activity of bortezomib alone and in combination with trail in human acute myeloid leukemia
    Conticello, C. M. S.
    Adamo, L.
    Vicari, L.
    Giuffrida, R.
    Iannolo, G.
    Moschetti, G.
    Anastasi, G.
    Palumbo, G. A.
    De Maria, R.
    Giustolisi, R.
    Di Raimondo, F.
    Gulisano, M.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 13 - 13
  • [3] Cytotoxic activity of bortezomib alone and in combination with trail in human acute myeloid leukemia
    Conticello, C.
    Adamo, L.
    Vicari, L.
    Giuffrida, R.
    Iannolo, G.
    Palumbo, G. A.
    Anastasi, G.
    Caruso, L.
    Moschetti, G.
    Cupri, A.
    Gulisano, M.
    De Maria, R.
    Giustolisi, R.
    Di Raimondo, F.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 52 - 53
  • [4] Phase I dose escalating trial of bortezomib (Veleade®) in combination with idarubicin and cytarabine in patients with acute myeloid leukemia.
    Attar, EC
    DeAngelo, DJ
    Ballen, KK
    Learner, E
    Trehu, EG
    Schenkein, DP
    Levine, JD
    Stone, RM
    Amrein, PC
    BLOOD, 2004, 104 (11) : 498A - 499A
  • [5] MEIS gene family in human acute myeloid leukemia.
    Afonja, O
    Smith, J
    Ohyashiki, K
    Ohyashiki, J
    Toyama, K
    Inghirami, G
    Takeshita, K
    BLOOD, 1997, 90 (10) : 293 - 293
  • [6] Acute myeloid leukemia.: Reply
    Löwenberg, B
    Burnett, AK
    NEW ENGLAND JOURNAL OF MEDICINE, 2000, 342 (05): : 358 - 359
  • [7] Cytogenetics in acute myeloid leukemia.
    Schoch C.
    Haferlach T.
    Current Oncology Reports, 2002, 4 (5) : 390 - 397
  • [8] Hypoplastic acute myeloid leukemia.
    Park, Hye-Won
    Lee, Je-Hwan
    Choi, Seong-Jun
    Lee, Jung-Hee
    Seol, Miee
    Lee, Young-Shin
    Ryu, Seong-Gil
    Kim, Keum Hee
    Jang, Seongsoo
    Seo, Eul-Joo
    Park, Chan-Jeoung
    BLOOD, 2006, 108 (11) : 202B - 202B
  • [9] Enhancing the antitumor activity of an engineered TRAIL-coated oncolytic adenovirus for treating acute myeloid leukemia
    Zixuan Wang
    Wenmo Liu
    Lizheng Wang
    Peng Gao
    Zhe Li
    Jiaxin Wu
    Haihong Zhang
    Hui Wu
    Wei Kong
    Bin Yu
    Xianghui Yu
    Signal Transduction and Targeted Therapy, 5
  • [10] Enhancing the antitumor activity of an engineered TRAIL-coated oncolytic adenovirus for treating acute myeloid leukemia
    Wang, Zixuan
    Liu, Wenmo
    Wang, Lizheng
    Gao, Peng
    Li, Zhe
    Wu, Jiaxin
    Zhang, Haihong
    Wu, Hui
    Kong, Wei
    Yu, Bin
    Yu, Xianghui
    SIGNAL TRANSDUCTION AND TARGETED THERAPY, 2020, 5 (01)
12345